HZNP - Brazil approves Horizon Therapeutics' Uplizna to treat autoimmune disease NMOSD

• Horizon Therapeutics ( NASDAQ: HZNP ) on Tuesday said its Uplizna drug had received Brazilian regulatory approval for the treatment of adults with a rare autoimmune disease.
• Brazil's drug regulator, ANVISA, approved Uplizna as a monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) with a certain criteria, HZNP said in a statement .
• NMOSD is a rare autoimmune disease that can result in inflammation of the optic nerve in the eye and the spinal cord, which in turn can cause vision loss and paralysis.
• According to HZNP, an estimated 10K people in Brazil have NMOSD.
• HZNP stock was marginally higher at $113.12 in afternoon trade.

For further details see: